What is NewLimit?

NewLimit is a biotechnology company working to radically extend human healthspan through epigenetic reprogramming.

Check out our website to learn more about our science and operating plan.

Visit our website

Why subscribe?

Subscribe to follow our progress as we develop reprogramming medicines. We believe that clear communication of our science is an essential part of achieving our mission.

Our blog is one venue we’ll be using to communicate. We’ll be sharing research plans, operating updates, and scientific results in an open, approachable format.

Join NewLimit

We’re always recruiting talented scientists and engineers to help us develop reprogramming medicines.

If you’re excited by our mission, please reach out.

Subscribe to NewLimit Blog

Updates on our progress toward radical extension of human healthspan


Jacob C. Kimmel

Head of Research @ NewLimit

Greg Johnson

Head of Machine Learning at NewLimit

Brian Armstrong

Co-founder and CEO at Coinbase